Skin Disorders News

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

Dupilumab demonstrated sustained effectiveness across patientreported outcome measures in adult and pediatric individuals with atopic dermatitis, according to a study.

MicroRNAs may indicate patients who have hereditary angioedema along with different phenotypes of the disease, according to a study published in Annals of Allergy, Asthma & Immunology.

Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.

With deep quantum modeling, researchers can go beyond the millions of distinct chemical structures previously accessible to scientists and explore 1060 possible combinations to find treatments for hereditary angioedema and other diseases.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

WASHINGTON — Using dupilumab to treat children with moderate to severe atopic dermatitis proved effective, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The use of a noninvasive skin tape strip at age 2 months can identify infants who are at risk for developing food allergy later, according to a study published in The Journal of Allergy and Clinical Immunology.